Siranbio
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Siranbio - overview
Established
2022
Location
Suzhou, Jiangsu, China
Primary Industry
Biotechnology
About
Based in Jiangsu, China and founded in 2022, Suzhou Siran Biotechnology Co. ,Ltd. , trading as Siranbio, is engaged in the research and development of siRNA therapeutics. In August 2026, Siranbio raised a Series A+ funding co-led by new investors IDG Capital and Riverhead Capital, with participation from CS Capital, Huatai Zijin Investment, YuanBio Venture, Lanchi Ventures, Zhongqi Capital, and Suzhou Haoping.
The company specializes in developing innovative small interfering RNA (siRNA) drugs to address unmet clinical needs across various disease areas, including viral infections, cardiovascular and metabolic disorders, autoimmune diseases, and central nervous system conditions. Key product lines include the SA1211 dual-target siRNA, aimed at achieving functional cures for hepatitis B, and the lead product SA030, a weight reduction siRNA drug. The company's revenue is generated by sales of their innovative therapies, positioned as solutions in the biopharmaceutical sector. The company will use the latest funding for the development of its siRNA dual-target and extrahepatic delivery pipelines for fat, muscle, myocardium, and kidney.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.siranbio.com
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.